TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein kin...

Full description

Bibliographic Details
Main Authors: Virginie Maire, Céline Baldeyron, Marion Richardson, Bruno Tesson, Anne Vincent-Salomon, Eléonore Gravier, Bérengère Marty-Prouvost, Leanne De Koning, Guillem Rigaill, Aurélie Dumont, David Gentien, Emmanuel Barillot, Sergio Roman-Roman, Stéphane Depil, Francisco Cruzalegui, Alain Pierré, Gordon C Tucker, Thierry Dubois
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23700430/pdf/?tool=EBI
id doaj-dcb4815980244faa8e17e979409ecdb7
record_format Article
spelling doaj-dcb4815980244faa8e17e979409ecdb72021-03-03T20:23:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6371210.1371/journal.pone.0063712TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.Virginie MaireCéline BaldeyronMarion RichardsonBruno TessonAnne Vincent-SalomonEléonore GravierBérengère Marty-ProuvostLeanne De KoningGuillem RigaillAurélie DumontDavid GentienEmmanuel BarillotSergio Roman-RomanStéphane DepilFrancisco CruzaleguiAlain PierréGordon C TuckerThierry DuboisTriple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein kinases that are overexpressed in human TNBC biopsies and whose silencing in TNBC cell lines causes cell death. A cohort including human BC biopsies obtained at Institut Curie as well as normal tissues has been analyzed at a gene-expression level. The data revealed that the human protein kinase monopolar spindle 1 (hMPS1), also known as TTK and involved in mitotic checkpoint, is specifically overexpressed in TNBC, compared to the other BC subgroups and healthy tissues. We confirmed by immunohistochemistry and reverse phase protein array that TNBC expressed higher levels of TTK protein compared to the other BC subgroups. We then determined the biological effects of TTK depletion by RNA interference, through analyses of tumorigenic capacity and cell viability in different human TNBC cell lines. We found that RNAi-mediated depletion of TTK in various TNBC cell lines severely compromised their viability and their ability to form colonies in an anchorage-independent manner. Moreover, we observed that TTK silencing led to an increase in H2AX phosphorylation, activation of caspases 3/7, sub-G1 cell population accumulation and high annexin V staining, as well as to a decrease in G1 phase cell population and an increased aneuploidy. Altogether, these data indicate that TTK depletion in TNBC cells induces apoptosis. These results point out TTK as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis associated subgroup of breast cancer.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23700430/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Virginie Maire
Céline Baldeyron
Marion Richardson
Bruno Tesson
Anne Vincent-Salomon
Eléonore Gravier
Bérengère Marty-Prouvost
Leanne De Koning
Guillem Rigaill
Aurélie Dumont
David Gentien
Emmanuel Barillot
Sergio Roman-Roman
Stéphane Depil
Francisco Cruzalegui
Alain Pierré
Gordon C Tucker
Thierry Dubois
spellingShingle Virginie Maire
Céline Baldeyron
Marion Richardson
Bruno Tesson
Anne Vincent-Salomon
Eléonore Gravier
Bérengère Marty-Prouvost
Leanne De Koning
Guillem Rigaill
Aurélie Dumont
David Gentien
Emmanuel Barillot
Sergio Roman-Roman
Stéphane Depil
Francisco Cruzalegui
Alain Pierré
Gordon C Tucker
Thierry Dubois
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
PLoS ONE
author_facet Virginie Maire
Céline Baldeyron
Marion Richardson
Bruno Tesson
Anne Vincent-Salomon
Eléonore Gravier
Bérengère Marty-Prouvost
Leanne De Koning
Guillem Rigaill
Aurélie Dumont
David Gentien
Emmanuel Barillot
Sergio Roman-Roman
Stéphane Depil
Francisco Cruzalegui
Alain Pierré
Gordon C Tucker
Thierry Dubois
author_sort Virginie Maire
title TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
title_short TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
title_full TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
title_fullStr TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
title_full_unstemmed TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
title_sort ttk/hmps1 is an attractive therapeutic target for triple-negative breast cancer.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein kinases that are overexpressed in human TNBC biopsies and whose silencing in TNBC cell lines causes cell death. A cohort including human BC biopsies obtained at Institut Curie as well as normal tissues has been analyzed at a gene-expression level. The data revealed that the human protein kinase monopolar spindle 1 (hMPS1), also known as TTK and involved in mitotic checkpoint, is specifically overexpressed in TNBC, compared to the other BC subgroups and healthy tissues. We confirmed by immunohistochemistry and reverse phase protein array that TNBC expressed higher levels of TTK protein compared to the other BC subgroups. We then determined the biological effects of TTK depletion by RNA interference, through analyses of tumorigenic capacity and cell viability in different human TNBC cell lines. We found that RNAi-mediated depletion of TTK in various TNBC cell lines severely compromised their viability and their ability to form colonies in an anchorage-independent manner. Moreover, we observed that TTK silencing led to an increase in H2AX phosphorylation, activation of caspases 3/7, sub-G1 cell population accumulation and high annexin V staining, as well as to a decrease in G1 phase cell population and an increased aneuploidy. Altogether, these data indicate that TTK depletion in TNBC cells induces apoptosis. These results point out TTK as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis associated subgroup of breast cancer.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23700430/pdf/?tool=EBI
work_keys_str_mv AT virginiemaire ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT celinebaldeyron ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT marionrichardson ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT brunotesson ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT annevincentsalomon ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT eleonoregravier ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT berengeremartyprouvost ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT leannedekoning ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT guillemrigaill ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT aureliedumont ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT davidgentien ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT emmanuelbarillot ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT sergioromanroman ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT stephanedepil ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT franciscocruzalegui ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT alainpierre ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT gordonctucker ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
AT thierrydubois ttkhmps1isanattractivetherapeutictargetfortriplenegativebreastcancer
_version_ 1714822800270688256